LG Chem Completes $571 Million AVEO Acquisition to Accelerate US Cancer Market Entry
核心洞察
LG Chem (搜索) completed its $571 million acquisition of US biotech firm AVEO Pharmaceuticals (搜索), strengthening its anti-cancer drug portfolio and accelerating entry into the US market.
The South Korean company announced a 2 trillion won ($1.6 billion) R&D investment plan through 2027, targeting the launch of four new cancer and metabolic disease treatments by 2030.
AVEO brings FDA-approved renal cancer (搜索) treatment Fotivda and specialized expertise in late-stage clinical trials and commercialization of cancer therapies.
LG Chem (搜索) Ltd. completed its $571 million acquisition of US biotech firm AVEO Pharmaceuticals (搜索) Inc. on Friday, marking a strategic milestone in the South Korean company's push to become a major player in the global cancer treatment market. The deal positions LG Chem to accelerate its entry into the US pharmaceutical market while strengthening its anti-cancer drug portfolio.
The acquisition aligns with LG Chem (搜索)'s ambitious goal to join the ranks of the world's top 30 pharmaceutical companies. To support this vision, the company announced a substantial 2 trillion won ($1.6 billion) investment in R&D of new medicines between 2023 and 2027.
Strategic Market Positioning
"AVEO will lead our growth in the cancer treatment market," said LG Chem (搜索) Vice Chairman Shin Hak-cheol. "We will take a leap to join the ranks of the global top 30 pharmaceutical companies with a focus on anti-cancer medicines."
The timing appears opportune, as the cancer therapy market is forecast to grow by an average of 10.4% annually, expanding from 250 trillion won in 2021 to 410 trillion won ($330 billion) by 2026. The US controls 40% of this market, making AVEO's established presence particularly valuable.
AVEO's Clinical Assets and Expertise
Founded in 2002 and based in Boston, AVEO brings significant clinical expertise to LG Chem (搜索)'s portfolio. The company developed Fotivda, an FDA-approved targeted therapy for renal cancer (搜索) that received regulatory approval in 2021. This treatment has been driving AVEO's sales growth and represents a proven commercial asset.
AVEO specializes in clinical trials and marketing of cancer therapies, capabilities that complement LG Chem (搜索)'s strengths. As a wholly owned subsidiary, AVEO will take charge of late-stage clinical trials in the pipeline and commercializing medicines, while LG Chem focuses on preclinical and early-stage clinical trials along with drug production.
Financial Projections and Pipeline Development
The acquisition's financial impact appears substantial. Sales at AVEO are projected to soar by approximately 60% year-on-year to 210 billion won in 2023, compared to 130 billion won in the previous year. US brokerage houses forecast AVEO's sales to more than double to 450 billion won by 2027.
The deal value of $571 million nearly matched the annual revenue of LG Chem (搜索)'s life science division in 2021, highlighting the acquisition's significance within the company's portfolio.
Pipeline and Development Strategy
LG Chem (搜索) currently has 20 drugs undergoing either preclinical or clinical trials, with nine focused on cancer treatments. The company's new drugs in preclinical development include cell therapies and immune checkpoint inhibitors (搜索), representing cutting-edge approaches to cancer treatment.
In the medium to long term, LG plans to transfer its portfolio of anti-cancer treatments to AVEO for commercialization in the US market. AVEO is currently conducting additional clinical trials to expand Fotivda's applications and developing new therapies for head and neck cancers (搜索).
Corporate Vision and Timeline
LG Chem (搜索) aims to introduce at least four new drugs targeting cancers and metabolic diseases (搜索) by 2030, pending FDA approval. The company previously announced its goal to generate approximately 2 trillion won in revenue from the biopharmaceutical business alone by 2027.
"Through the latest acquisition, LG Chem (搜索) is now a step closer to realizing our vision, which is to offer humans a better life through science and innovation," said LG Chem CEO Shin Hak-cheol. "We will focus on fostering Aveo the foothold to lead our anticancer business for the goal of becoming one of the top 30 biopharmaceutical companies by maximizing the synergy effects."
Pharmaceuticals represent one of LG Chem (搜索)'s three growth pillars, alongside battery and eco-friendly materials, positioning the AVEO acquisition as central to the company's long-term strategic direction.